Testing safety of FB418 in healthy people
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial studies a new drug called FB418 to see if it's safe and how the body handles it. It first tests single doses in younger healthy men, then multiple doses, and also includes an optional group for healthy older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For younger group: healthy men aged 19–55
- For older group: healthy men or women over 60 who cannot become pregnant
- Must not have used nicotine products for at least 3 months
- Body mass index between 18 and 32
- No major medical or mental health conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called FHND1002 in healthy adults aged 18 to 45. The goal is to check its safety, how well the body tolerates it, and how it is processed. It is one of the first tests in humans.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This early-phase trial tests an experimental oral medication called FB-101 in healthy adult men to check its safety and how the body processes it. It's a first step to see if the drug is safe enough for future studies in patients.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
Hear when a new Parkinson Disease Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.